Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: Randomised, double-blind, controlled, phase 2 trials

Authors

Ahmet Z Uluer, Harvard University
Ronald C Rubenstein, Washington University School of Medicine in St. Louis
et al.

Journal

Lancet Respiratory Medicine

Publication Date

6-1-2023

Volume

11

Issue

6

First Page

550

Last Page

562

Document Type

Open Access Publication

DOI

10.1016/S2213-2600(22)00504-5

Rights and Permissions

Uluer AZ, MacGregor G, Azevedo P, Indihar V, Keating C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Rubenstein RC, Taylor-Cousar JL, Tullis E, Yonker LM, Chu C, Lam AP, Nair N, Sosnay PR, Tian S, Van Goor F, Viswanathan L, Waltz D, Wang LT, Xi Y, Billings J, Horsley A; VX18-121-101; VX18-561-101 Study Groups. Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials. Lancet Respir Med. 2023 Jun;11(6):550-562. doi: 10.1016/S2213-2600(22)00504-5. © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.

Recommended Citation

Uluer, Ahmet Z; Rubenstein, Ronald C; and et al., "Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: Randomised, double-blind, controlled, phase 2 trials." Lancet Respiratory Medicine. 11, 6. 550 - 562. (2023).
https://digitalcommons.wustl.edu/oa_4/2346

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.